C4 Therapeutics, Inc.

NasdaqGS:CCCC 株式レポート

時価総額：US$361.4m

C4 Therapeutics マネジメント

マネジメント 基準チェック /44

C4 Therapeuticsの CEO はAndrew Hirschで、 Sep2020年に任命され、 の在任期間は 5.67年です。 の年間総報酬は$ 2.94Mで、 23.6%給与と76.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.12%を直接所有しており、その価値は$ 443.50K 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と7.8年です。

主要情報

Andrew Hirsch

最高経営責任者

US$2.9m

報酬総額

CEO給与比率23.63%
CEO在任期間5.7yrs
CEOの所有権0.1%
経営陣の平均在職期間5.3yrs
取締役会の平均在任期間7.8yrs

経営陣の近況

Recent updates

分析記事 • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Seeking Alpha • Mar 10

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

Summary C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment. Valuation remains highly discounted (EV/sales 1.66x), but future success hinges on cemsidomide trial outcomes and regulatory milestones. Read the full article on Seeking Alpha
分析記事 • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
分析記事 • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
分析記事 • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
分析記事 • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
分析記事 • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
分析記事 • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
分析記事 • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
分析記事 • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
分析記事 • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
分析記事 • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
分析記事 • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
分析記事 • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
分析記事 • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
分析記事 • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

CEO報酬分析

C4 Therapeutics の収益と比較して、Andrew Hirsch の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

報酬と市場: Andrewの 総報酬 ($USD 2.94M ) は、 US市場 ($USD 2.72M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Andrewの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Andrew Hirsch (54 yo)

5.7yrs
在職期間
US$2,940,975
報酬

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Andrew Hirsch
CEO, President & Director5.7yrsUS$2.94m0.12%
$ 443.5k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.32%
$ 1.2m
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs & Treasurer2.7yrsUS$1.48m0.041%
$ 148.2k
Leonard M. Reyno
Chief Medical Officer2.8yrsUS$1.64m0.023%
$ 83.6k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno dataデータなしデータなし
Mark Mossler
Chief Accounting Officer2.7yrsデータなし0.0053%
$ 19.0k
Paige Mahaney
Chief Scientific Officer1.6yrsデータなし0.016%
$ 59.6k
Courtney Solberg
Senior Manager of Investor Relationsno dataデータなしデータなし
Kelly Schick
Chief People Officer5.3yrsデータなし0.035%
$ 127.5k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.2yrsデータなしデータなし
Christopher Nasveschuk
Senior Vice President of Chemistry5.3yrsデータなしデータなし
Roy Pollock
Senior Vice President of Biological Sciences7.3yrsデータなしデータなし
5.3yrs
平均在職期間
54yo
平均年齢

経験豊富な経営陣: CCCCの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称ポジション在職期間報酬所有権
Andrew Hirsch
CEO, President & Director5.6yrsUS$2.94m0.12%
$ 443.5k
Kenneth Anderson
Co-Founder10.4yrsUS$85.50k0.32%
$ 1.2m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.5yrsデータなしデータなし
Christopher Bowden
Member of Clinical Advisory Boardno dataデータなしデータなし
Steven Hoerter
Independent Director1.5yrsUS$90.31kデータなし
Christopher Kirk
Member of Scientific Advisory Board9.5yrsデータなしデータなし
Ross Levine
Member of Scientific Advisory Board8.8yrsデータなしデータなし
Ronald H. Cooper
Independent Chairman1.9yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board6.7yrsデータなしデータなし
Scott Armstrong
Member of Scientific Advisory Board8.8yrsデータなしデータなし
Utpal Koppikar
Independent Director4.2yrsUS$100.50k0.0051%
$ 18.6k
Beni Wolf
Member of Clinical Advisory Boardno dataデータなしデータなし
7.8yrs
平均在職期間
54yo
平均年齢

経験豊富なボード: CCCCの 取締役会 は 経験豊富 であると考えられます ( 7.8年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 21:37
終値2026/05/21 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

C4 Therapeutics, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15

アナリスト機関
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets